Maegim

Stock search

Search by company name, 6-digit code, or Korean initials (e.g. ㅅㅅㅈㅈ)

☆한국어

JIN YANG PHARMACEUTICAL. CO., LTD

진양제약007370KOSDAQSector: Pharma & Biotech
₩4,0500.25%Market cap ₩57.2BAs of Sep 1, 2026 close · updated once daily
Market cap
₩57.2B
#1077 in KOSDAQ
2.6x
Sector median 16.3x (profitable cos.)
0.36x
Sector median 1.61x
3.0%
Sector median 0.0%
A
Grade A65.9 ptsTop 20% of 2,523 graded stocksPreviously BMethodology v2.0
Financial strength
49.3/100
Growth momentum
42.3/100
Price attractiveness
97.6/100
Shareholder Return
94.1/100

As of Sep 1, 2026 close · This grade is not a buy/sell recommendation — it is information mechanically scored from public data using a fixed formula.

How to read this grade
SACurrentBCDF

Toward S means a higher total-score band; toward F, a lower band. Badges are distinguished by ink intensity and shape (fill, outline, dashed) — never by hue.

Maegim maps a total score — built from sector-relative percentile scoring — onto fixed, predefined thresholds to assign one of six bands, S to F. This stock is scored by the same formula as all 2,523 graded stocks and is currently in band A with a total score of 65.9 points.

How grades are computed →What grades do and don’t mean →What the grade does not reflect →

Position within sector

Mechanically selected indicators in the top or bottom 30% of sector percentiles · among 250 stocks in Pharma & Biotech

1-year closing price

Loading closing price history…
 
Low ₩3,440High ₩5,980
Latest close
Price change by period
1W
0.60%
1M
6.00%
3M
0.40%
1Y
29.10%

As of the Sep 1, 2026 close · updated once daily · a factual record computed from closing prices only; dividends are not included, and this is not a buy or sell signal.

1

Financial strength

49.3/100
How much debt does it carry relative to equity?
67.5%
Sector median 51.6%
Sector lowhighBottom 37.4% in sector
Can it cover what's due within a year?
52.3%
Sector median 191.7%
Sector lowhighBottom 7.9% in sector
How much of revenue becomes profit?
2.1%
Sector median -2.4%
Sector lowhighTop 41.2% in sector
How much did it earn on its own capital?
13.9%
Sector median -4.5%
Sector lowhighTop 7.1% in sector

Source filing: annual report (separate) — view original ↗

2

Growth momentum

42.3/100
How much did revenue grow in a year?
6.5%
Sector median 6.4%
Sector lowhighTop 49.3% in sector
Has it grown steadily over three years?
16.5%
Sector median 4.9%
Sector lowhighTop 16.8% in sector
Did core profits grow in a year?
-78.4%
Sector median 3.6%
Sector lowhighBottom 11.8% in sector
Are core profits higher than three years ago?
-77.3%
Sector median 3.5%
Sector lowhighBottom 23.4% in sector

Financial trend

Revenue

Growth & margin

Revenue growth Operating margin

Year over year — alongside the sector median

This stock Sector median

A factual chart of confirmed annual results from annual reports — the same source as the grading indicators. Not a buy or sell signal.

Source filing: annual report (separate) — view original ↗

3

Price attractiveness

97.6/100
Is the price expensive relative to earnings?
2.6x
Sector median P/E of profitable peers 16.3x · 58% loss-making
Sector lowhighTop 0.6% in sector
Is the price expensive relative to book value?
0.36x
Sector median 1.61x
Sector lowhighTop 4.3% in sector

Valuation uses the Sep 1, 2026 close and market cap

4

Shareholder Return

Single-indicator axis94.1/100
Does the company actually pay dividends?
3.0%
Sector median 0.0%
Sector lowhighTop 5.9% in sector

Dividend per share (annual)

Cash dividend per common share as stated in annual reports. ₩0 means no dividend that year.

Dividends & treasury shares

Total cash dividends (FY2025)
₩2.1B

Source: annual report (DART) — dividend allocation & total shares

Source filing: annual report (separate) — view original ↗

Financial checklist

Based on the FY2025 annual report · year-over-year comparison · determined on Sep 2, 2026

Of 9 items: 3 met · 6 not met · 0 not computable

Not metMetNot computable

Positive net income
Whether net income (attributable to owners where available) is above zero.
Met
₩22.3B
Positive operating cash flow
Whether cash flow from operations is above zero.
Met
₩1.5B
Return on assets up
Whether net income over beginning total assets rose from the prior year.
Not met
24.8% → 9.8%
Operating cash flow exceeds net income
Whether operating cash flow is greater than net income.
Not met
₩1.5B vs ₩22.3B
Liabilities-to-assets ratio down
Whether total liabilities as a share of total assets fell from the prior year.
Met
47.3% → 40.3%
Current ratio up
Whether current assets over current liabilities rose from the prior year.
Not met
219.0% → 52.3%
Shares outstanding not increased
Whether common shares issued did not increase from the prior year. Increases from bonus issues and stock dividends are also counted.
Not met
12,651,173 → 14,134,587
Operating margin up
Whether operating income over revenue rose from the prior year.
Not met
10.3% → 2.1%
Asset turnover up
Whether revenue over beginning total assets rose from the prior year.
Not met
0.95x → 0.53x

A record of facts determined by fixed rules from the financial statements in the latest annual report. Not used in grading, and not a buy or sell signal. Source filing: annual report (separate) — view original ↗

Grade change history

Jul 23, 2026B→A

Methodology version change (v2.0 applied)

Jul 15, 2026BVersion v1

First calculation

Grade changes are a factual record produced from public data by a fixed formula; they do not signal future changes.

Recent filings for this stock

Last 120 days · monitored filing types only
Periodic report filedAug 13, 2026Source ↗
Periodic report filedMay 15, 2026Source ↗

View in the filings calendar →